Lorcaserin (also know as APD-356) is a neurotransmittering anti-obesity medication evolved by Arena Pharmaceuticals Inc. Last year, on December 22 a New Drug Application has been directed to the FDA in the USA, and at the moment is waiting for its endorsement.
Mechanism Overview
Lorcaserin is a medication effecting the 5-HT2C receptor, and during the laboratorial experiments it demonstated sensible selectivity for 5-HT2C over other receptors in a row. 5HT2C receptors are settled nearly exceptionally in the brain zone, and can also be settled in the plexus choroideus, bark, cerebellum, and hypothalamus.
The stimulation of 5-HT2C receptors in the brain is known to improve weight reduction by the sense of satiation, which is highly promoted by clinical researches and theory.
Despite it is generally believed that 5HT2C receptors assist to control appetite likewise mood or endocrine system, the precise process of appetite control is not totally learned. Lorcaserin has demonstated 100:1 selectivity for 5HT2C receptor versus the other types.
